Memo - USA Surveillance Strategy (Sept 2021 from non-FloodLAMP Healthcare Attorney) The follow-up email summarizes guidance that COVID-19 surveillance testing is generally not regulated by FDA or CLIA when samples lack unique identifiers and no individual results are returned, citing FDA and CDC language. It recommends coordinating with local public health officials, structuring groups large enough to support anonymized aggregate reporting, and ensuring testing is administered by appropriately trained personnel consistent with state law. primary file regulatory surveillance Memo - USA Surveillance Strategy (Sept 2021 from non-FloodLAMP Healthcare Attorney).md regulatory/surveillance/Memo - USA Surveillance Strategy (Sept 2021 from non-FloodLAMP Healthcare Attorney).md 2021_09_01 docx docx CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/ 593 826 gfile-url xfile-github-download-url pdf-gdrive-url pdf-github-url github-markdown-url github-markdown-download-url web-pdf-url web-slides-url youtube-url web-url